<DOC>
	<DOCNO>NCT00392314</DOCNO>
	<brief_summary>Recently publish study demonstrate high event free survival patient normal interim PET/CT high hazard ratio progression interim positive ( pathological ) study . These finding strongly support integration interim PET decision point adjustment chemotherapy.This study use minimal therapy consider safe accord predefined risk factor patient interim negative PET . Those pathologic interim study consider high risk patient dose escalation therapy.remission rate , event free survival overall survival evaluate .</brief_summary>
	<brief_title>Tailored Therapy Hodgkin Lymphoma Using Early Interim Therapy PET Therapy Decision .</brief_title>
	<detailed_description>study aim tailor therapy order administer low cumulative dose therapy yet consider safe order reduce early late therapy related complication . patient divide accord risk factor sub group early favorable , early unfavorable , advanced disease score le 3 point high 3 point . Early Interim PET carry Further therapy base study result .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Hodgkin lymphoma patient age 1860 early disease advance disease score le 3 age 1860 year patient advance disease score 3 high classical Hodgkin lymphoma WBC 3500 platelets 100000 creatinin less 2.0 mg bilirubin le 2.0 mg absolute neutrophil count 1000 unless bone marrow involvement If marrow involve , patient low count ANC 1000 may include . Positive serology HIV bilirubin 2 mg/dl creatinin 2 mg/dl lactate woman pregnant patient old 60 year high risk disease score 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>hodgkin lymphoma</keyword>
	<keyword>PET/CT</keyword>
	<keyword>Therapy</keyword>
</DOC>